Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Derek Menkedick

Neurology Centerville, OH Doctor of Osteopathy

NPI 1699137364 CMS profile 4219450

1975 Miamisburg Centerville Rd, Centerville, OH 45459

Open in the dashboard

General payments

$20,016

947 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$405,472 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Derek Menkedick of Centerville, OH is reported in the CMS Open Payments database as having received $20,016 across 947 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $405,472 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 83rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,557 143
2024 General $4,342 174
2023 General $3,821 195
2022 General $2,672 144
2021 General $3,339 188
2020 General $1,110 58
2019 General $1,175 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Derek Menkedick
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Derek Menkedick were reported at $3,557. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Derek Menkedick Neurology median Middle half National median
2019 $1,175 $474 $118–$2,177 $163
2020 $1,110 $367 $82–$2,309 $114
2021 $3,339 $438 $104–$2,547 $132
2022 $2,672 $442 $103–$2,388 $149
2023 $3,821 $464 $119–$2,312 $160
2024 $4,342 $468 $119–$2,323 $164
2025 $3,557 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,528 130 payments
  2. EMD Serono, Inc. $2,347 50 payments
  3. US WorldMeds, LLC $1,800 89 payments
  4. Biogen, Inc. $1,455 46 payments
  5. Novartis Pharmaceuticals Corporation $871 66 payments
  6. Lilly USA, LLC $796 54 payments
  7. Genentech USA, Inc. $790 24 payments
  8. UCB, Inc. $727 32 payments
  9. Alexion Pharmaceuticals, Inc. $621 25 payments
  10. Neurocrine Biosciences, Inc. $620 40 payments
  11. Other $7,460 391 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $19,295 933 payments
  2. Consulting Fee $450 3 payments
  3. Education $164 2 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $107 9 payments
Products named General payments · program years 2019–2025
  1. QULIPTA $1,378 60 payments
  2. Gocovri Amantadine $1,163 37 payments
  3. UBRELVY $1,045 50 payments
  4. TYSABRI $671 11 payments
  5. INGREZZA $607 39 payments
  6. OCREVUS $599 20 payments
  7. KESIMPTA $572 39 payments
  8. NURTEC ODT $534 34 payments
  9. GOCOVRI Neurology $513 43 payments
  10. BOTOX $503 38 payments
  11. Other $11,348 619 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

1,415

Median for Neurology: 833

Drug cost

$404,493

Median for Neurology: $202,670

Branded share of claims

21%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Kesimpta Pen Ofatumumab Brand 13 $132,090
Botox Onabotulinumtoxina Brand 52 $63,242
Cuvitru Immun Glob G(Igg)/Gly/Iga Ov50 Brand 12 $58,735
Ubrelvy Ubrogepant Brand 45 $50,754
Nurtec Odt Rimegepant Sulfate Brand 23 $33,643
Qulipta Atogepant Brand 13 $14,560
Aimovig Autoinjector Erenumab-Aooe Brand 18 $13,512
Reyvow Lasmiditan Succinate Brand 15 $11,266
Ajovy Autoinjector Fremanezumab-Vfrm Brand 12 $8,645
Gabapentin Generic 229 $2,337

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$258,355

Of which drugs: $181,725

Medicare patients

493

Average age 73

Services billed

12,579

275 women, 218 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Depression 42%
Diabetes 41%
Ischemic heart disease 35%
Chronic kidney disease 34%
Heart failure 27%
Alzheimer's or dementia 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 13 6,200 $30,933

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 41 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Gocovri
$1,145 — —
UBRELVY
$250 45 —
QULIPTA
$230 13 —
ULTOMIRIS
$203 — —
Leqembi
$179 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 41 with Patron

Records

947 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record